APLM vs. PMN, XLO, UNCY, LEXX, MRKR, EYEN, VYNE, ACXP, CARA, and BCTX
Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include ProMIS Neurosciences (PMN), Xilio Therapeutics (XLO), Unicycive Therapeutics (UNCY), Lexaria Bioscience (LEXX), Marker Therapeutics (MRKR), Eyenovia (EYEN), VYNE Therapeutics (VYNE), Acurx Pharmaceuticals (ACXP), Cara Therapeutics (CARA), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.
Apollomics (NASDAQ:APLM) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
Apollomics received 2 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 80.00% of users gave Apollomics an outperform vote.
19.1% of Apollomics shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 10.3% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 0.00 equaled ProMIS Neurosciences'average media sentiment score.
ProMIS Neurosciences has lower revenue, but higher earnings than Apollomics.
Apollomics presently has a consensus price target of $2.00, suggesting a potential upside of 392.73%. ProMIS Neurosciences has a consensus price target of $8.00, suggesting a potential upside of 315.67%. Given Apollomics' higher possible upside, equities research analysts plainly believe Apollomics is more favorable than ProMIS Neurosciences.
Apollomics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Summary
ProMIS Neurosciences beats Apollomics on 6 of the 11 factors compared between the two stocks.
Get Apollomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apollomics Competitors List
Related Companies and Tools
